Daewon Pharmaceutical reported on the 15th that its sales in the first quarter of this year amounted to 157.8 billion won, a decrease of 0.32% compared to the same period last year, and its operating profit recorded 9.4 billion won, down 3.5% from the same period last year. The profit margin decreased slightly from 9.5% last year to 6.0%.
The company analyzed that the increase in cost of sales, rising research and development expenses, and the restructuring of affiliated companies have affected the decline in operating profit margin.
A Daewon Pharmaceutical official said that "the normalization and profitability improvement of the acquired affiliates are ongoing, and with the upcoming performance improvement, we will continue to grow with a strategy focused on strengthening marketing for core products and improving profitability."